ReviewTherapeutics and clinical risk management2017

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Eva Havrdova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.